ArticleInternational journal of general medicine2025
Plasma Semaphorin 3A as a Potential Biomarker for Cognitive Impairment in Cerebral Small Vessel Disease.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum Semaphorin Alterations in Psoriasis: Links to Metabolic Status Rather than Disease Severity.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sema3A plays an essential role in the nervous system and is thought to regulate the entire course of the inflammatory response. This study aimed to explore the potential association between plasma Sema3A levels and cerebral small vessel disease (CSVD). Methods: This study enrolled patients with recent small subcortical infarct (RSSI) and 100 healthy controls (HCs). Sema3A levels were measured during the acute phase (≤3 days) and the subacute phase (14-30 days) of RSSI. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA). Brain magnetic resonance imaging (MRI) was used to evaluate CSVD imaging features. The study analyzed the association between Sema3A, CSVD imaging features, and cognitive impairment. Results: Plasma Sema3A levels during the acute phase were markedly higher in RSSI patients than in HCs ( Conclusion: Plasma Sema3A levels during the acute phase were elevated in RSSI patients and were linked to cognitive impairment through the mediating roles of WMH and LI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.